News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Files Two Melanoma Drugs for U.S., Europe Approvals


8/3/2012 7:53:07 AM

GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, said it submitted two experimental melanoma medicines to regulators in the U.S. and Europe for approval following trials that it deemed successful two months ago. Glaxo filed dabrafenib with both the European Medicines Agency and the U.S. Food and Drug Administration, the London- based company said in a statement today. Glaxo is also applying for U.S. approval of trametinib, and will seek European clearance for trametinib in “coming months.”

Read at BusinessWeek
Read at Chicago Tribune
Read at InPharm.com
Read at Market Watch
Read at Wall Street Journal

comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES